Companies › Guangzhou JOYO Pharma
4 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Oncology, Respiratory, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JYP0015 Pan-RAS inhibitor targeting the active (ON) form of wild-type and mutant RAS | KRAS, NRAS, HRAS | Phase 2 | Solid Tumor | Dec 2026 |
| SC1011 antifibrotic agent | – | Phase 2 | Idiopathic Pulmonary Fibrosis | Dec 2026 |
| JYP0061 | – | Phase 2 | Neuromyelitis Optica Spectrum Disorders | – |
| JYP0322 ROS1 tyrosine kinase inhibitor | ROS1 | Phase 1 | Protein Kinase Inhibitors | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06697535 | JYP0061 | Phase 2 | Neuromyelitis Optica Spectrum Disorders | Neurology | Feb 2026 |
| NCT06125327 | SC1011 | Phase 2 | Idiopathic Pulmonary Fibrosis | Respiratory | Dec 2026 |
| NCT06895031 | JYP0015 | Phase 2 | Solid Tumor | Oncology | Dec 2026 |
| NCT06128148 | JYP0322 | Phase 1 | Protein Kinase Inhibitors | Oncology | Dec 2027 |
Blueprint Medicines Avistone Biotechnology Ranok Therapeutics (Hangzhou) Genfleet Therapeutics (Shanghai) TaiRx
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.